- Home
- CRGX vs QSI Comparison
CRGX vs QSI Comparison
Compare CRGX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- QSI
- Stock Information
- Founded
- CRGX 2021
- QSI 2013
- Country
- CRGX United States
- QSI United States
- Employees
- CRGX N/A
- QSI N/A
- Industry
- CRGX
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- QSI Health Care
- Exchange
- CRGX Nasdaq
- QSI Nasdaq
- Market Cap
- CRGX 621.4M
- QSI 633.2M
- IPO Year
- CRGX 2023
- QSI N/A
- Fundamental
- Price
- CRGX $12.39
- QSI $2.24
- Analyst Decision
- CRGX Strong Buy
- QSI Buy
- Analyst Count
- CRGX 6
- QSI 2
- Target Price
- CRGX $31.80
- QSI $3.25
- AVG Volume (30 Days)
- CRGX 280.8K
- QSI 60.2M
- Earning Date
- CRGX 11-12-2024
- QSI 02-27-2025
- Dividend Yield
- CRGX N/A
- QSI N/A
- EPS Growth
- CRGX N/A
- QSI N/A
- EPS
- CRGX N/A
- QSI N/A
- Revenue
- CRGX N/A
- QSI $2,266,000.00
- Revenue This Year
- CRGX N/A
- QSI $193.90
- Revenue Next Year
- CRGX N/A
- QSI $173.18
- P/E Ratio
- CRGX N/A
- QSI N/A
- Revenue Growth
- CRGX N/A
- QSI 232.26
- 52 Week Low
- CRGX $10.91
- QSI $0.61
- 52 Week High
- CRGX $33.92
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- CRGX 39.66
- QSI 49.02
- Support Level
- CRGX $10.91
- QSI $1.85
- Resistance Level
- CRGX $15.75
- QSI $2.68
- Average True Range (ATR)
- CRGX 1.20
- QSI 0.83
- MACD
- CRGX -0.11
- QSI -0.15
- Stochastic Oscillator
- CRGX 30.08
- QSI 9.95
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.